ERBB2 and neoplasm: Together, these data suggest that the tumor infiltration and functionality of T cells in tumors, as the likely primary effector cells for HCT-mono-mIL12-mediated antitumor efficacy (19), are affected by the anti-HER2 binding kinetics.